title: A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.
abstract: Tyrosine kinases orchestrate key cellular signaling pathways and their dysregulation is often associated with cellular transformation. Several recent cases in which inhibitors of tyrosine kinases have been successfully used as anticancer agents have underscored the importance of this class of proteins in the development of targeted cancer therapies. We have carried out a large-scale loss-of-function analysis of the human tyrosine kinases using RNA interference to identify novel survival factors for breast cancer cells. In addition to kinases with known roles in breast and other cancers, we identified several kinases that were previously unknown to be required for breast cancer cell survival. The most surprising of these was the cytosolic, nonreceptor tyrosine kinase, Bruton's tyrosine kinase (BTK), which has been extensively studied in B cell development. Down regulation of this protein with RNAi or inhibition with pharmacological inhibitors causes apoptosis; overexpression inhibits apoptosis induced by Doxorubicin in breast cancer cells. Our results surprisingly show that BTK is expressed in several breast cancer cell lines and tumors. The predominant form of BTK found in tumor cells is transcribed from an alternative promoter and results in a protein with an amino-terminal extension. This alternate form of BTK is expressed at significantly higher levels in tumorigenic breast cells than in normal breast cells. Since this protein is a survival factor for these cells, it represents both a potential marker and novel therapeutic target for breast cancer.
authors.affiliation: Department of Biomedical Sciences, Gen*NY*Sis Center for Excellence in Cancer Genomics, University at Albany, Rensselaer, NY.
authors.forename: Cheryl
authors.initials: C
authors.lastname: Eifert
authors.forename: Xianhui
authors.initials: X
authors.lastname: Wang
authors.forename: Leila
authors.initials: L
authors.lastname: Kokabee
authors.forename: Antonis
authors.initials: A
authors.lastname: Kourtidis
authors.forename: Ritu
authors.initials: R
authors.lastname: Jain
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Gerdes
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Conklin
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D017209:Apoptosis / Q000502:physiology*; D001483:Base Sequence; D001940:Breast / Q000737:chemistry; D001943:Breast Neoplasms / Q000737:chemistry / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D008969:Molecular Sequence Data; D011505:Protein-Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D034622:RNA Interference
chemical_list: D007527:Isoenzymes; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human
references.citation: J Clin Invest. 2008 Nov;118(11):3574-81
references.pmid: 18982164
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: Cancer Res. 1999 May 15;59(10):2292-6
references.pmid: 10344731
references.citation: J Bioenerg Biomembr. 2011 Jun;43(3):247-55
references.pmid: 21647634
references.citation: Am J Pathol. 2008 Nov;173(5):1540-50
references.pmid: 18832579
references.citation: Breast Cancer Res. 2006;8(6):215
references.pmid: 17096862
references.citation: BMC Genomics. 2011 Oct 14;12:505
references.pmid: 21999571
references.citation: Curr Pharm Des. 2004;10(15):1757-66
references.pmid: 15180538
references.citation: Oncogene. 2000 Dec 7;19(52):6043-52
references.pmid: 11146556
references.citation: Biochem Biophys Res Commun. 2002 Dec 6;299(3):510-5
references.pmid: 12445832
references.citation: J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):3-11
references.pmid: 16947082
references.citation: Int J Cancer. 1995 Apr 10;61(2):170-6
references.pmid: 7705943
references.citation: Cancer Res. 2006 Jun 1;66(11):5648-55
references.pmid: 16740702
references.citation: Genome Res. 2002 Mar;12(3):458-61
references.pmid: 11875034
references.citation: FASEB J. 2005 Nov;19(13):1884-6
references.pmid: 16166198
references.citation: Immunol Rev. 2009 Mar;228(1):58-73
references.pmid: 19290921
references.citation: Nat Genet. 2005 Nov;37(11):1281-8
references.pmid: 16200065
references.citation: Cell Signal. 2004 Nov;16(11):1249-61
references.pmid: 15337524
references.citation: Cell Signal. 2010 Jul;22(7):984-1002
references.pmid: 20096351
references.citation: Ernst Schering Res Found Workshop. 2007;(61):1-21
references.pmid: 17249494
references.citation: Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11
references.pmid: 14681370
references.citation: Biochemistry. 2009 Mar 10;48(9):2021-32
references.pmid: 19206206
references.citation: Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
references.pmid: 20615965
references.citation: Reprod Toxicol. 2008 Feb;25(2):256-62
references.pmid: 18242054
references.citation: Lancet. 2002 Feb 9;359(9305):481-6
references.pmid: 11853794
references.citation: Cancer Res. 2006 Aug 15;66(16):8058-64
references.pmid: 16912182
references.citation: Science. 2006 May 26;312(5777):1175-8
references.pmid: 16728632
references.citation: Biol Cell. 2012 Nov;104(11):641-57
references.pmid: 22804687
references.citation: Oncogene. 2000 Nov 20;19(49):5651-61
references.pmid: 11114746
references.citation: Oncogene. 2008 Feb 14;27(8):1095-105
references.pmid: 17700528
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11005-10
references.pmid: 16043716
references.citation: Nature. 2001 May 17;411(6835):355-65
references.pmid: 11357143
references.citation: Mol Cancer Res. 2012 May;10(5):573-87
references.pmid: 22522456
references.citation: Nat Cell Biol. 2005 Jun;7(6):591-600
references.pmid: 15864305
references.citation: Nat Rev Cancer. 2005 Apr;5(4):251-62
references.pmid: 15803153
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11312-6
references.pmid: 8248245
references.citation: J Biol Chem. 1999 Jan 15;274(3):1646-56
references.pmid: 9880544
references.citation: Genome Res. 2006 Jan;16(1):55-65
references.pmid: 16344560
references.citation: Mol Cancer Res. 2008 Mar;6(3):435-45
references.pmid: 18337450
references.citation: Mol Cell Biol. 2006 Jul;26(14):5284-99
references.pmid: 16809766
references.citation: J Biol Chem. 2007 Nov 9;282(45):32689-98
references.pmid: 17823122
references.citation: PLoS Biol. 2007 Sep 4;5(10):e254
references.pmid: 17803354
references.citation: Nat Genet. 2007 Jul;39(7):870-4
references.pmid: 17529973
references.citation: Nature. 2007 Oct 4;449(7162):557-63
references.pmid: 17914389
references.citation: N Engl J Med. 2005 Jul 14;353(2):172-87
references.pmid: 16014887
references.citation: Nucleic Acids Res. 2003 Jan 1;31(1):374-8
references.pmid: 12520026
references.citation: J Immunol. 1994 Jan 15;152(2):557-65
references.pmid: 8283037
references.citation: Leukemia. 2006 Jun;20(6):1047-54
references.pmid: 16598311
references.citation: Trends Genet. 2008 Apr;24(4):167-77
references.pmid: 18329129
references.citation: Oncogene. 1991 Apr;6(4):659-63
references.pmid: 1851551
references.citation: Blood. 2006 Nov 1;108(9):3135-42
references.pmid: 16835385
references.citation: Eur J Immunol. 1993 Dec;23(12):3109-14
references.pmid: 8258324
references.citation: Mol Cancer. 2011 Jul 21;10:86
references.pmid: 21777462
references.citation: Expert Opin Investig Drugs. 2012 Mar;21(3):355-61
references.pmid: 22300471